DUBLIN--(BUSINESS WIRE)--The "China Blood Product Industry Report, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which has further opened up the blood product market. In 2020, the lot release volume of blood products in China sustained growth, hitting 101.31 million bottles, a year-on-year upsurge of 12.7%.

Wherein, the lot release volume of human albumin rose 14.78% on an annualized basis, making up 60%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 12.92% in the total showed a year-on-year increase of 11.78%; that of human tetanus immunoglobulin soared by 76.7% and accounted for 6.9%; other products like human fibrinogen, human prothrombin complex and human coagulation factor VIII took relatively low shares.

The Health Commission of Yunnan Province proposed to set up 24 plasma collection stations (adding 20 new ones based on the 4 pilot ones) across the province, according to the Plan of Yunnan Province for Setting up Plasma Collection Stations (2020-2023) (Exposure Draft) it issued in December 2020. Currently, Shanghai Blood Products under Beijing Tiantan Biological Products has 2 pilot stations operated in Yunnan, having collected a total of around 42 tons. Also, the document indicates blood product companies that construct production bases in Yunnan will be given priority to build. With its plasma station expansion plan, Yunnan may set the pace in loosening the restrictions on new plasma stations. On one estimate, China had boasted 273 plasma collection stations by the end of 2020.

In 2020, the pandemic suspended plasma collection in China for two months, stopping collection volume growth. Chinese Academy of Medical Sciences predicted a like-on-like slump of 22%, or 1,000 tons, in plasma collection volume in the first half of 2020.

Companies with more plasma stations, such as Beijing Tiantan Biological Products, Shanghai RAAS Blood Products, China Biologic Products and Hualan Biological Engineering gather pace and will scramble for larger shares on the strength of their great ability to collect plasma, promising their far higher industry status. In 2019, Beijing Tiantan Biological Products, Hualan Biological Engineering, China Biologic Products and Shanghai RAAS Blood Products took a higher combined market share of up to 34.47%.

In recent years, there were an increasing number of mergers and acquisitions among blood products companies in China. Leaders roared ahead mainly by way of mergers and acquisitions, an expansion model supplemented by self-built plasma stations. Mergers and acquisitions have been a key part of their long-term strategic plans.

China Blood Product Industry Report, 2020-2027 highlights the following:

• China blood product industry (policy, status quo, market structure, supply & demand, market size, competitive pattern);
• China blood product market segments (status quo, bid price, competitive pattern);
• 13 blood product companies (operation, revenue structure, gross margin, blood product business, etc.);
• Summary and forecast.

Key Topics Covered:

1. Blood Products

1.1 Definition

1.2 Classification

1.3 Recombinant Blood Products

1.4 Industry Chain

1.5 Features

2. China Blood Product Market

2.1 Policies

2.2 Status Quo

2.3 Market Structure

2.4 Supply and Demand

2.4.1 Supply

2.4.2 Demand

2.5 Market Size

2.6 Competitive Pattern

3. China Blood Product Market Segments

3.1 Human Albumin

3.1.1 Status Quo

3.1.2 Bid Price

3.1.3 Market Structure

3.1.4 Competitive Pattern

3.1.5 Prospects

3.2 Human Immunoglobulin (pH4) for Intravenous Injection

3.3 Coagulation Factor VIII

3.4 Human Hepatitis B Immunoglobulin

3.5 Human Immunoglobulin

3.6 Human Prothrombin Complex

3.7 Human Tetanus Immunoglobulin

3.8 Human Rabies Immunoglobulin

4. Major Enterprises

4.1 China Biologic Products (CBPO)

4.1.1 Profile

4.1.2 Operation

4.1.3 Revenue Structure

4.1.4 Gross Margin

4.1.5 R&D Investment

4.1.6 Blood Products Business

4.1.7 Guizhou Taibang Biological Products Co., Ltd.

4.1.8 Shandong Taibang Biological Products Co., Ltd.

4.1.9 Xi'an Huitian Blood Products Co., Ltd.

4.2 Hualan Biological Engineering Co., Ltd.

4.3 Shanghai RAAS Blood Products Co., Ltd.

4.4 Beijing Tiantan Biological Products

4.5 Guangdong Shuanglin Bio-Pharmacy

4.6 Jiangxi Boya Bio-Pharmaceutical

4.7 Weiguang Biological Products

4.8 Beijing Bohui Innovation Technology

4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.

4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

4.11 Shanxi Kangbao Biological Product Co., Ltd.

4.12 Green Cross China

4.13 Nanyue Biopharming Corporation Ltd.

5. Summary and Forecast

5.1 Summary

5.2 Development Trends

5.2.1 The Industry Continues to Boom

5.2.2 Industry Integration Speeds Up, Concentration Rises Further

5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry

5.2.4 Plasma Collection Volume Increases Progressively

5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise

5.2.6 Downstream Demand Stimulates the Industry

5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Growth of the Industry

5.2.8 COVID-19 Pandemic Brings Development Opportunities to Domestic Companies

For more information about this report visit https://www.researchandmarkets.com/r/a5iu6w

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900